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Mode of action (MOA) analysis provides a systematic de-
scription of key events leading to adverse health effects in animal
bioassays for the purpose of informing human health risk
assessment. Uncertainties and data gaps identiﬁed in the MOA
analysis may also be used to guide future research to improve
understanding of the MOAs underlying a speciﬁc toxic response
and foster development of toxicokinetic and toxicodynamic
models. An MOA analysis, consistent with approaches outlined
in the MOA Framework as described in the Guidelines for
Carcinogen Risk Assessment, was conducted to evaluate small
intestinal tumors observed in mice chronically exposed to
relatively high concentrations of hexavalent chromium (Cr(VI))
in drinking water. Based on review of the literature, key events in
the MOA are hypothesized to include saturation of the reductive
capacity of the upper gastrointestinal tract, absorption of Cr(VI)
into the intestinal epithelium, oxidative stress and inﬂammation,
cell proliferation, direct and/or indirect DNA modiﬁcation, and
mutagenesis. Although available data generally support the
plausibility of these key events, several unresolved questions and
data gaps were identiﬁed, highlighting the need for obtaining
critical toxicokinetic and toxicodynamic data in the target tissue
and in the low-dose range. Experimental assays that can address
these data gaps are discussed along with strategies for compar-
isons between responsive and nonresponsive tissues and species.
This analysis provides a practical application of MOA Framework
guidance and is instructive for the design of studies to improve
upon the information available for quantitative risk assessment.
Key Words: risk assessment; carcinogenesis; hexavalent
chromium; Cr(VI); mode of action.
Mode of action (MOA) analysis is a systematic description
of likely key events that lead to adverse health effects
following exposure to environmental toxicants (Dellarco and
Wiltse, 1998). The U.S. Environmental Protection Agency
(EPA) has formally described MOA analysis in the context of
cancer risk assessment in an MOA Framework described in the
‘‘Guidelines for Carcinogen Risk Assessment’’ (U.S. EPA,
2005), and others have expanded this concept to the assessment
of noncancer endpoints (Bogdanffy et al., 2001; Julien et al.,
2009; Meek et al., 2003; Seed et al., 2005; U.S. EPA, 2005).
MOA analysis has historically been performed to judge the
likelihood that adverse outcomes observed in animals will
occur in humans, as well as to support the choice of low-dose
extrapolation approaches. MOA analysis may also identify data
gaps that can be used to design studies aimed at improving or
further substantiating the hypothesized key events in an MOA.
Hexavalent chromium (Cr(VI)) provides a useful case study
for applying MOA analysis for purposes of identifying data
gaps to guide future research. Our goal was to critically
examine the peer-reviewed literature to identify articles
pertinent to the oral carcinogenicity of Cr(VI) for purposes of
proposing a plausible MOA hypothesis underlying the
carcinogenic response observed in mice exposed to Cr(VI) in
drinking water for 2 years (NTP, 2008b; Stout et al., 2009a).
This MOA analysis was conducted in accordance with the U.S.
EPA MOA Framework (U.S. EPA, 2005) and identiﬁed key
data gaps that could be used to guide future research on Cr(VI).
This effort, along with a review of key literature related to key
events in the hypothesized MOA, is described in detail in this
paper.
BACKGROUND
Chromium is a naturally occurring element that primarily
exists in two oxidized states: Cr(VI) and trivalent chromium
(Cr(III)). The latter form is considered a micronutrient with
a putative biological role in insulin sensitivity (Anderson,
2000) and is reported to exhibit limited acute and chronic
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1990; NTP, 2008a; Stout et al., 2009b). In contrast, Cr(VI) is
a strong oxidizing agent and is acutely toxic under certain
exposure scenarios. Based on evidence of lung cancer among
workers in certain industries with occupational exposure to
Cr(VI), this compound has been classiﬁed as a known human
carcinogen by inhalation routes of exposure (IARC, 1990).
Because of the differences in toxicity by species, health risk
assessment and heath-based environmental standards for
chromium are typically valence-speciﬁc. Further, valence
state and environmental chemistry—speciﬁcally, oxidation-
reduction (redox) chemistry, inform the mobility, bioavail-
ability, bioaccessibility, and toxicity of chromium in the
environment (James et al., 1997). Much of the Cr(VI) in
the environment is attributable to anthropogenic sources—due
primarily to applications in wood preservatives, pigments,
anticorrosive primers, metal plating and releases as a result of
some ferrometal and stainless steel operations, and the
combustion of fossil fuel (IARC, 1990). Cr(VI) also occurs
naturally and is prevalent in groundwater in certain areas (Oze
et al., 2007). As a result, human exposures are likely to be
widespread. For example, Cr(VI) exists at low concentrations
in approximately one-third of the California drinking water
supply (CDHS, 2009).
Until recently, Cr(VI) was not considered to pose a cancer
risk by the oral route of exposure. In fact, the EPA Integrated
Risk Information System ﬁle for Cr(VI), prepared in 1998,
states that ‘‘[n]o data were located in the available literature
that suggested that Cr(VI) is carcinogenic by the oral route of
exposure’’ (U.S. EPA, 1998). In promulgating the federal
drinking water standard (maximum contaminant level) for
total chromium, the U.S. EPA concluded that ‘‘the body’s
normal physiology provides detoxiﬁcation for CrVI which
provides protection from the oral toxicity’’ (U.S. EPA, 1991).
Reduction of Cr(VI) to Cr(III) prior to absorption is thought to
offer protection against Cr(VI) carcinogenicity from oral intake
at environmentally relevant exposure levels (De Flora, 2000;
Proctor et al., 2002a). However, absorption from the
gastrointestinal (GI) tract and reduction in the GI lumen are
recognized to be competing kinetic processes (O’Flaherty
et al., 2001). Thus, several authors have argued that Cr(VI)
could pose a cancer risk from ingestion at sufﬁcient doses
(Costa and Klein, 2006; McCarroll et al., 2010; Sedman et al.,
2006).
In 2008, the National Toxicology Program (NTP) completed
a 2-year cancer bioassay for Cr(VI) in drinking water. In this
study, investigators found that Cr(VI) caused tumors in the
small intestines of mice and the oral mucosa of rats at
exposures of 20–180 mg/l Cr(VI) in the form of sodium
dichromate dihydrate (SDD) (NTP, 2008b; Stout et al., 2009a).
Statistically signiﬁcant increases relative to concurrent controls
were observed at   60 mg/l Cr(VI). Interestingly, the tumors
occurred along the alimentary canal (portal of entry) and were
characterized as relatively rare in both species and were
generally only found near the termination of the study (NTP,
2008b; Stout et al., 2009a). Because Cr(VI) was administered
at concentrations that greatly exceed expected human expo-
sures (Supplementary fig. 1), there are many questions
regarding dose-response and risk to humans at environmentally
relevant exposures. The small intestine tumors were observed
only in mice and were dose dependent, and the tumor type and
incidence followed a logical pattern from benign adenoma to
malignant carcinoma. The tumors were preceded in dose and
time by diffuse hyperplasia, whereas comparable responses
were not observed in the rat small intestine (Table 1). The oral
cavity tumors in rats were not preceded by any obvious adverse
pathology. Considering that many mutagens induce tumors at
multiple sites and with relatively short time to tumor
development (McCarroll et al., 2010; U.S. EPA, 2007), the
hyperplasia associated with the small intestinal tumors are
suggestive of a nonmutagenic MOA, where mutation is
unlikely to be the initiating key event in the intestinal
tumorigenesis. However, the intracellular reduction of Cr(VI)
can form chemical species that can potentially react directly
with DNA (O’Brien et al., 2003; Salnikow and Zhitkovich,
2008; Zhitkovich, 2005). Hence, further studies are necessary
to elucidate the MOA for these tumors.
APPLICATION OF MOA AND HUMAN RELEVANCE
FRAMEWORKS
U.S. EPA (2005) deﬁnes MOA as ‘‘a sequence of key events
and processes, starting with interaction of an agent with a cell,
proceeding through operational and anatomical changes, and
resulting in cancer formation.’’ Although there is some
ambiguity concerning whether the above deﬁnition excludes
pharmacokinetics from the MOA, we concur with others who
clearly include toxicokinetics as key events in the MOA (Julien
et al., 2009). Because of the known dependence of biochemical
and toxicological properties on chromium speciation, it is
impossible to place tissue responses from different chromium
compounds into their proper context without consideration of
toxicokinetics to arrive at comparative internal doses. EPA
deﬁnes a key event as ‘‘an empirically observable and
quantiﬁable precursor step that is itself a necessary element
of the MOA or is a biologically based marker for such an
element.’’ Importantly, the MOA Framework stresses that the
MOA for each tumor site should be evaluated and that:
An agent may work by more than one mode of action, both
at different sites and at the same tumor site. Thus the mode of
action and human relevance cannot necessarily be generalized
to other toxic endpoints or tissues or cell types without
additional analyses.
Thus, it may be inappropriate to extrapolate ﬁndings from
various systems, tissues, and cell types (e.g., lung carcinoma)
to a previously unrecognized tumor such as intestinal car-
cinoma; but rather data should be evaluated (and obtained if
necessary) for tumors of interest.
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human relevance framework that has been developed and
described by several investigators (Meek et al., 2003; Seed
et al., 2005). As shown in Figure 1, the ﬁrst step in the human
relevance framework is to consider whether the MOA in
animals is well established. Considering that the MOA
underlying the development of intestinal tumors in mice is
not known, the highlighted blue box represents the current
status for understanding human relevance of these tumors.
Nevertheless, there are human data available to begin
considering the plausibility and relevance of our hypothesized
MOA for humans.
Summary of the Key Events in the Hypothesized Cr(VI)
MOA for Mouse Intestinal Tumors
We postulate that the MOA for mouse intestinal tumors is
a combination of proliferative pressure and direct and/or
indirect (e.g., epigenetic) DNA modiﬁcation. The MOA is
hypothesized to be a direct consequence of exceeding the
extracellular reductive capacity of the lumen of the upper GI
tract (i.e., mouth and stomach). Sustained saturation of the
reductive capacity of the upper GI tract results in continuous
delivery of Cr(VI) to the intestinal lumen at doses sufﬁcient to
initiate subsequent key events. The second proposed key event
is absorption of Cr(VI) from the intestinal lumen into the
epithelial tissues of the small intestine. Both the ﬁrst and the
second key events are empirically measurable pharmacokinetic
parameters that are critical to understanding target tissue dose
and construction of pharmacokinetic and pharmacodynamic
models. It is important to consider that NTP also recently
conducted a 2-year bioassay for Cr(III), administered as
chromium picolinate, and neither neoplastic nor nonneoplastic
effects were observed despite very high doses (NTP, 2008b;
Stout et al., 2009b). Hence, if Cr(VI) is reduced to Cr(III)
before cellular absorption, toxicity is unlikely to occur.
Following absorption into epithelial tissues, the third proposed
key event is oxidative stress, which in turn is expected to lead
to tissue damage and inﬂammation. The fourth hypothesized
key event is cell proliferation, consistent with the diffuse
hyperplasia in the NTP studies (NTP, 2007, 2008b). The ﬁfth
hypothesized key event involves DNA modiﬁcation that may
occur as a result of intracellular reduction of Cr(VI) to
potentially DNA reactive and oxidative species, which in turn
can lead to genetic or epigenetic changes to DNA. DNA
modiﬁcation might also occur as a result of prolonged
proliferative pressure. Finally, the sixth hypothesized key
event involves mutagenesis. The sequence of key events in our
hypothesized MOA is outlined in Figure 2. Support for each
proposed key event is provided below. It should be noted that
TABLE 1
Summary of Select Neoplastic and Nonneoplastic Lesions in the NTP 2-Year Bioassay. Incidence of Nonneoplastic and Neoplastic
Lesions in the Intestine and Oral Cavity
Cr(VI) drinking water concentration, mg/l
0 5 20 60 180
Findings in the small intestines of female mice (and rats)
a
Duodenum
Histiocytic inﬁltration 0/50 (0/46)
b 0/50 (0/49) 4/50 (1/48) 33/50** (30/46)** 40/50** (47/50)**
Focal hyperplasia 0/50 0/50 1/50 2/50 0/50
Diffuse hyperplasia 0/50 16/50** 35/50** 31/50** 42/50**
Adenoma 0/50 0/50 2/50
# 13/50*** 12/50***
Carcinoma 0/50 0/50 0/50 1/50
# 6/50*
Jejunum
c
Histiocytic inﬁltration 0/50 0/50 0/50 2/50 8/50**
Diffuse hyperplasia 0/50 2/50 1/50 0/50 8/50**
Adenoma 0/50 1/50 0/50 2/50
# 5/50*
Carcinoma 1/50 0/50 2/50
# 2/50
# 1/50
Combined tumors in small intestine
d 1/50 1/50 4/50
# 17/50*** 22/50***
Findings in rat oral mucosa or tongue
e
Female, combined papilloma and carcinoma 1/50 1/50 0/50 2/50
# 11/50**
Male, combined papilloma and carcinoma 0/50 1/50 0/49 0/50 7/49**
Note. Detailed results and statistical analyses can be found in NTP (2008b) and Stout et al. (2009a).
aFor brevity, the intestinal results for males are not shown. Similar positive and negative ﬁndings were reported for male mice and rats, respectively.
bHistiocytic inﬁltration was the only histopathological response reported in the male and female rat duodenum.
cNo lesions were reported for the jejunum in male and female rats.
dNo intestinal tumors were observed in male or female rats.
eNo tumors were observed in the mouse oral mucosa or tongue.
*p   0.05, **p   0.01 by poly-3 test, ***p   0.001 by poly-3 test;
#exceeded historical control range.
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recognized that some events may occur concomitantly. Finally,
it should be noted that this MOA differs from that recently
proposed by McCarroll et al., (2010) which suggests that DNA
damage and mutagenesis occur prior to cell proliferation.
Description of the Key Events in the Proposed MOA for
Small Intestine Tumors
Key Event 1: Saturation of Cr(VI) Reductive Capacity in the
Upper GI Tract
Cr(VI) is much more readily absorbed into cells than Cr(III),
and thus, extracellular reduction of Cr(VI) to Cr(III) in the gut
lumen before cellular absorption is a critical kinetic process
limiting toxicity (De Flora, 2000; De Flora et al., 1997;
Donaldson and Barreras, 1966; Febel et al., 2001; Kerger et al.,
1996; U.S. EPA, 1998). At high drinking water concentrations,
it is anticipated that exceedence of reduction capacity can lead
to increased tissue uptake. Several lines of evidence suggest
that all the drinking water concentrations in the NTP (2008b)
study may have exceeded the ability of the rodent stomach to
reduce Cr(VI). For instance, toxicokinetic data from the NTP
(2007) study as well as Sutherland et al. (2000) suggest that
dose-dependent transitions in chromium disposition occur in
rodents somewhere between 3 and 10 mg/l Cr(VI) in drinking
water (Fig. 3). Recently, several authors (Collins et al. 2010;
Stern 2010; Stout et al., 2009a) have concluded that
toxicokinetic data collected in NTP (2008b) indicate that
reductive capacity was not exceeded because ‘‘tissue concen-
tration data were consistent with a linear or supralinear dose-
response’’ (Stout et al., 2009a). These authors anticipate a
positive increase in the slope of chromium tissue concentration
that would be indicative of saturation of reductive capacity and
increased accumulation of chromium. Stern (2010) plotted the
mouse data in Figure 3 as a line graph and concluded that the
data were linear or supralinear and that a threshold for Cr(VI)
reduction had not been achieved (Supplementary fig. 2A).
FIG. 1. General schematic of the human relevance framework as developed by Meek et al. (2003) and revised by Seed et al. (2005). The box highlighted in
blue represents the current status of the MOA for intestinal tumors in animals. Adapted from Seed et al. (2005).
FIG. 2. Hypothesized MOA for Cr(VI) carcinogenesis in the GI tract.
MOA FRAMEWORK FOR THE ORAL CARCINOGENICITY OF CR(VI) 23However, Figure 3 and Supplementary figure 2B suggest that
the change in slope anticipated by these authors at or near
carcinogenic drinking water concentrations may have begun at
the lowest concentration, i.e., 5 mg/l Cr(VI), employed in the
2-year bioassay (NTP, 2008b), indicating saturation of re-
ductive capacity at all doses.
Tissue data from both NTP studies (NTP, 2007, 2008b)
indicate that mice had higher concentrations of chromium in
the stomach, liver, and blood than rats (Figs. 3 and 4) and
suggest that mice may have lower capacity to reduce Cr(VI) to
Cr(III) in the stomach lumen than rats or an enhanced ability to
absorb chromium in the intestines. Differences in tissue
chromium concentration may explain why hyperplasia was
observed in the mouse duodenum at all doses in the 2-year
NTP (2008b) study but not in the rat duodenum. Such
differences in tissue concentrations may reﬂect differences in
extracellular reductive capacities in the GI tract in the two
species and/or differences in surface area or membrane
transport. GI reductive capacity is determined, in part, by
gastric ﬂuid composition, pH, and gastric acid production rate
(De Flora et al., 1997; Donaldson and Barreras, 1966).
Measures of gastric ﬂuid reduction rates and capacities between
rodent species are currently not available but would be
informative for understanding the pharmacokinetics and human
relevance given the different tissue responses in the small
intestines of mice and rats. Interestingly, Stern (2010)
performed trend tests on the data in Figure 4 and found that
a linear relationship was observed with the entire dose range as
well as with just the two lowest concentrations—and again
concluded that these data suggest that saturation of reductive
capacity was not achieved in NTP (2008b). However, he did
not report such a test for the data in Figure 3, which contains
lower concentrations (see Supplementary fig. 2A).
Notably, the lowest drinking water concentration tested in
the NTP (2008b) study exceeds the 95th percentile for Cr(VI)
concentrations in U.S. drinking water by approximately 300-
fold (Supplementary fig. 1); thus, whether Cr(VI) is reduced to
Cr(III) in the stomach at concentrations expected in the
environment is critical for assessing human relevance for risk
assessment. Thus, quantiﬁcation of key event 1 is important for
understanding the differential responses observed in rats and
mice as well as to evaluate the potential human relevance of the
intestinal tumors observed in mice.
Although data exist for the reductive capacity of human
gastric ﬂuid, these data are limited and no comparable data
exist for rodents. Proctor et al. (2002b) found that in simulated
human gastric ﬂuid, the rate of Cr(VI) reduction was similar
across variables of pH, concentration of Cr(VI), fasted or fed
conditions, and in real human gastric ﬂuid as compared with
simulated ﬂuid. However, at lower pH (1.5 as compared with
4.5 or 7), the reductive capacity (total mass of Cr(VI) reduced
per volume of ﬂuid) of simulated gastric ﬂuid was signiﬁcantly
increased. The reductive capacity of real human stomach ﬂuid
was 10-fold higher than that of simulated ﬂuid at the same pH
FIG. 3. Total chromium (Cr) concentration in the blood of rats, mice, and guinea pigs following 21 days of exposure to the indicated drinking water
concentrations, milligrams per liter Cr(VI) as SDD (data are taken from NTP, 2007). For each species, these data suggest a dose-dependent transition in the
disposition of chromium somewhere between 3 and 10 mg/l Cr(VI) in drinking water. The inset shows a similar dose-dependent transition in total Cr body burden
between 3 and 10 mg/l Cr(VI) in drinking water administered as potassium dichromate for 44 weeks, which was reproduced with kind permission from Springer
Science & Business Media: Biological Trace Element Research, Rats Retain Chromium in Tissues Following Chronic Ingestion of Drinking Water Containing
Hexavalent Chromium, 74, 2000, 41–53, Sutherland, Zhitkovich, Kluz, and Costa, Figure 5, Copyright 2000 by Humana Press Inc.
24 THOMPSON ET AL.(approximately 1.5 consistent with fasting conditions) (Proctor
et al. 2002b). Collins et al. (2010), Stern (2010), and Stout
et al. (2009a) suggest that the reductive capacity of the rodent
stomach can be extrapolated from data on the reductive
capacity of the human gastric ﬂuid using bodyweight scaling
because factors affecting reduction are under metabolic control
(i.e., dependent on gastric acid secretion) as compared with pH,
which is known to vary by species (Supplementary table 2).
However, differences in the anatomy and physiology of the
rodent stomach, as compared with that of humans, are
signiﬁcant (Supplementary table 2), and reduction rate and
capacity may not be readily extrapolated on the basis of
bodyweight scaling. Thus, development of physiologically
based pharmacokinetic (PBPK) models, based on measured
species-speciﬁc reduction rates and capacities for gastric ﬂuid,
as well as measures of target tissue dose, are needed to more
reliably quantify interspecies extrapolations.
Key Event 2: Uptake into the Small Intestine Epithelial
Mucosa
Cr(VI) that escapes reduction in the stomach is likely to be
absorbed into the epithelial cells of the intestinal mucosa, due
in part to the high surface area of the tissue. Cr(VI) primarily
exists as chromate at neutral pH and as hydrochromate below
ap Ho f6( Zhitkovich, 2005); the former has isostructural
similarity with physiological sulfate and phosphate ions and
thus readily enters cells through the anion transport channels
(De Flora, 2000; Markovich, 2001; Salnikow and Zhitkovich,
2008; Zhitkovich, 2005). It is generally believed that Cr(VI)
uptake is mediated by the solute carrier (SLC) 4A anion
transporter family and SLC4A1 in particular. This has been
surmised based on ﬁndings that erythrocytes express high
levels of the SLC4A1 anion transporter and readily take up
Cr(VI) (Cohen et al., 1993; Markovich, 2001). The SLC4A1
protein product, anion exchanger 1 (AE1, also known as band
3), is inhibited by stilbene disulfonates (Cohen et al., 1993;
Little et al., 1996; Markovich, 2001). These inhibitors have
also been shown to reduce Cr(VI) uptake into cells in vitro;
however, the inhibitors are not speciﬁc to AE1 (Kudrycki et al.,
1990). Studies in rats indicate that SLC4A1 is abundantly
expressed in erythrocytes and kidney but comparatively limited
elsewhere. Nevertheless, within the rat GI tract, SLC4A1
expression is highest in the duodenum (Kudrycki et al., 1990).
The SLC4A2 family member is more abundantly expressed
than SLC4A1 in the rat small intestines (Kudrycki et al., 1990;
Rossmann et al., 2000). Unlike SLC4A1, SLC4A2 function is
regulated by both intracellular and extracellular pH and has
several N-terminal variants (Alper, 2009; Alper et al., 1999).
Thus, differences in Cr(VI) uptake across species might be
because of differences in the expression and regulation (e.g., by
intracellular pH) of SLC4A genes in the GI tract. Therefore,
research studies designed to examine SLC gene expression and
function (e.g., ability to transport sulfate and/or Cr(VI)) may be
important to characterize interspecies difference in Cr(VI) uptake
into the small intestine epithelial mucosa and to determine target
tissue dose for pharmacokinetic and pharmacodynamic models.
FIG. 4. Total chromium in the glandular stomach and liver in male rats and female mice after 6 (A), 13 (B), 182 (C), and 371 (D) days of exposure. Tissue
concentration data are mean micrograms of Cr per gram tissue ± SE reported in tabular form in NTP (2008b). The milligrams per kilogram per day dose is the
average daily ingested dose of Cr(VI) over the study duration as reported in Stout et al. (2009a).
MOA FRAMEWORK FOR THE ORAL CARCINOGENICITY OF CR(VI) 25In contrast to Cr(VI), Cr(III) only enters the cell passively or
perhaps by endocytosis. As will be discussed for the third
hypothesized key event, the toxicity of Cr(VI) is generally
believed to be the result of intracellular reduction of Cr(VI) to
Cr(III). Thus, intracellular absorption as Cr(VI) is a necessary
key event. This is supported by the results of the recently
completed NTP 2-year bioassay where rats and mice were
exposed to high concentrations of Cr(III) in drinking water but
no biologically signiﬁcant neoplastic or nonneoplastic lesions
were found despite the accumulation of chromium in tissues
(NTP, 2008a; Stout et al., 2009b). Hence, there are distinctly
different effects depending on the chromium species ingested.
Key Event 3: Oxidative Stress Leading to Tissue Damage and
Inﬂammation
Within the cell, enzymes may play a role in reducing Cr(VI)
to Cr(III). However, much of the intracellular reduction
involves binding of Cr(VI) to low molecular weight thiols
such as glutathione (GSH) and cysteine, as well as antioxidants
like ascorbate (Fig. 5A)( De Flora et al., 1985; O’Brien et al.,
2003; Zhitkovich, 2005). The cellular abundance of these
reactants can differ across species, and reaction rates are
estimated to differ greatly for ascorbate, GSH, and cysteine
(O’Brien et al., 2003). Reduction of Cr(VI) can also lead to the
formation of less stable intermediates such as Cr(V) and Cr(IV)
as well as thiol radicals (O’Brien et al., 2003; Yao et al., 2008).
Another potential pathway involves reduction of Cr(VI) to
Cr(V) by molecular oxygen, which results in the generation of
reactive oxygen species (ROS) (Liu and Shi, 2001). This in
turn leads to the formation of hydrogen peroxide that can be
removed by catalase, conjugation with GSH (perhaps compet-
ing with GSH-mediated Cr(VI) reduction), as well as by
Fenton reactions with iron. Peroxide can also undergo Fenton
reactions with Cr(V), thereby reforming Cr(VI) and hydroxide
radicals (Liu and Shi, 2001). Thus, sustained exposure to
Cr(VI) might lead to oxidative stress (Fig. 5B).
Understanding chromium disposition is complicated by
several factors. For instance, Cr(V) and Cr(IV) are typically
short-lived species. Unlike Cr(VI), Cr(V) and Cr(III) are
paramagnetic and can be traced by magnetic resonance
imaging albeit not easily distinguished (Liu and Shi, 2001).
As recently noted by Nickens et al. (2010), there are several
limitations inherent to in vitro studies on chromium. For
example, many cultured cells have abnormally low antioxidant
levels, which, coupled with dose rate issues when applying
Cr(VI) and other constituents, obfuscate conclusions regarding
Cr(VI) and oxidative stress. Moreover, the redox status and
compliment of anion transporters likely differ across cell type
as well as condition of conﬂuence and terminal differentiation
(Markovich, 2001). Thus, in vivo data from target tissues of
interest are necessary to better understand the role of oxidative
stress in the MOA underlying intestinal tumors in mice.
Direct evidence for oxidative stress in intestinal tissue (from
any species) is limited. Acute exposure of rats to Cr(VI) by oral
gavage led to decreased activities of intestinal mucosal
enzymes, decreased levels of sulfhydryls, increased lipid
peroxidation, and mixed alterations of antioxidant enzymes
(e.g., GSH reductase and glutathione-S-transferase); however,
FIG. 5. Simpliﬁed Cr(VI) reduction schemes. (A) Reduction of Cr(VI) by low molecular weight ligands (L). Adapted from Zhitkovich (2005). (B) Reduction
of Cr(VI) by molecular oxygen (adapted from Liu and Shi 2001). Note that reactions are simpliﬁed and do not show mass balance. SOD, superoxide dismutase;
Cys, cysteine; GSSG, oxidized GSH; GPx, glutathione peroxidase; Vc, ascorbate.
26 THOMPSON ET AL.these bolus doses (100 mg/kg potassium chromate) were
greater than the highest doses in the NTP study (~17 to 25 mg/kg
SDD) (Arivarasu et al., 2008). Mice exposed to 5 or 20 mg/l
Cr(VI) as SDD in drinking water for 9 months exhibited no
evidence of oxidative DNA damage in the intestine (De Flora
et al., 2008), suggesting that if oxidative stress occurred in the
small intestines it was not sufﬁcient to induce oxidative DNA
damage. It is also conceivable that prolonged exposure to
Cr(VI) can lead to adaptive changes that ameliorate oxidative
damage. For example, differences in oxidative markers were
observed in the rat intestinal mucosa following acute (3 days)
and subchronic (30 days) exposure to potassium dichromate
(Sengupta et al., 1990). Generally, acute exposure led to
signiﬁcant decreases in GSH and activity of antioxidant
enzymes, whereas prolonged exposure led to a more mixed
response with the activity of some enzymes being unaltered
while others were increased or decreased.
Oxidative stress is well recognized to induce inﬂammation.
Broadly, oxidative stress leads to activation of nuclear factor-jB
(NF-jB) and subsequent downstream pathways resulting in
the release of cytokines. This broad mechanism is implicated
in airway inﬂammation, intestinal inﬂammation, and certain
cancers (Kruidenier and Verspaget, 2002; Rahman and
MacNee, 2000; Roberts et al., 2009). Cr(VI)-induced in-
ﬂammation may play a critical role in lung cancer. A single
intranasal exposure to particulate Cr(VI) (~1 mg/kg) was
shown to induce lung inﬂammation that required nearly 21
days to fully resolve (Beaver et al., 2009). Repeated (about
once every 2 weeks) intranasal administration of particulate
Cr(VI) resulted in an inﬂammatory reaction following each
exposure, as well as signs of chronic inﬂammation in the
bronchiolar and alveolar regions of the lung (Beaver et al.,
2009). In contrast, nasal instillation of soluble Cr(VI) at 0.25 or
0.75 mg/kg for 3 consecutive days resulted in no overt signs of
inﬂammation at 1 and 21 days postexposure (O’Hara et al.,
2006). O’Hara et al. (2006) also showed that these concen-
trations signiﬁcantly downregulated the antioxidant gene heme
oxygenase-1 in the lung, suggesting that Cr(VI) may induce
only mild inﬂammatory responses at these exposures (consis-
tent with pathology data), but concomitantly alter the
regulation of antioxidant enzymes. It should be noted that
similar exposures have been shown to induce DNA damage
and apoptosis in rodent lungs; some of these effects were
partially mitigated by oral administration of N-acetylcysteine
(D’Agostini et al., 2002; Izzotti et al., 1998, 2002). Taken
together, these data suggest that exposure to Cr(VI) is likely to
induce oxidative stress in tissues that come in direct contact
with the compound, including the lung via inhalation and the
highly absorbent intestinal mucosa following oral ingestion of
high concentrations of Cr(VI) in drinking water.
Clear evidence for chronic inﬂammation in the duodenum
was not observed in the mouse intestines at the doses tested in
the 2-year NTP study. However, histiocytic inﬁltration was
observed in the duodenum of both rats and mice in the 90-day
and 2-year NTP studies (Tables 1 and 2). This inﬁltration was
characterized as small clusters of macrophages as opposed to the
more normal randomly distributed pattern. The NTP study
authors stated that the biological signiﬁcance of histiocytic
inﬁltration is not known. Considering that histiocytic inﬁltration
was observed as early as 90 days, the prolonged presence of
leukocytes in tissues might be a sign of chronic mild
inﬂammation. This might be important, as cytokines released
from macrophages have been implicated in carcinogenesis
within the large intestines (He et al.,2 0 0 6 ; Li et al.,2 0 0 9 ).
Both redox status and inﬂammation can activate similar
pathways—particularly via NF-jB and activation protein-1
(Rahman and MacNee, 2000; Roberts et al., 2009). The latter
protein is a heterodimer of c-fos and jun protooncogenes with
important roles in cell proliferation and differentiation. These
and other transcription factors are regulated, in part, by cellular
oxidative and nitrosative status (Marshall et al., 2000). In recent
reviews on the carcinogenicity of chromium, it is noted that
dysregulation of genes involved in cell death, DNA repair, and
cell cycle can induce an epigenetic state that ultimately favors
DNA damage (Holmes et al., 2008; Nickens et al., 2010).
Nickens et al. (2010) posit that cell death pathways, inherently
protective from cancer, may become disrupted by inﬂammatory
responses to Cr(VI). Thus, redox status and inﬂammation can
promote cell proliferation and inhibit programed cell death,
thereby increasing the chance of genetic damage.
Key Event 4: Cell Proliferation
Data from the NTP Cr(VI) studies indicate that diffuse
intestinal hyperplasia occurred in the duodenum of mice at all
doses examined and as early as 90 days of exposure. Although
tumor incidence did not increase in the 2-year study except in
the highest doses (Table 1), it is conceivable that proliferation
(1) preceded tumorigenesis, (2) was incidental to tumorigen-
esis, and/or (3) was elevated because of tumorigenesis.
However, the NTP (2008b) study authors stated that the
diffuse hyperplasia observed in the mouse small intestines was
‘‘consistent with regenerative hyperplasia secondary to
TABLE 2
Spatiotemporal Depiction of Diffuse Hyperplasia and
Histiocytic Inﬁltration
Duration 13 Weeks 104 Weeks
Mg/l Cr(VI)   22   44   350   5   60   60   180   180   180
Location Duodenum Duodenum Jejunum
Pathology DH HI Neo DH HI Neo DH HI Neo
Species
Rat — O —— O — ———
Mouse OO— O O O OOO
DH, diffuse hyperplasia; HI, histiocytic inﬁltration; Neo, neoplasm.
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describe the observed intestinal hyperplasia in the 90-day
study. Focal hyperplasia, a potentially preneoplastic lesion
(Stout et al., 2009a), was not statistically signiﬁcantly elevated
at any dose but was present in some animals (Table 1). Figure 6
highlights the relationship between intestinal neoplasms,
intestinal hyperplasia, and histiocytic inﬁltration. Although
histiocytic inﬁltration was noted in both rodent species in the
90-day and 2-year NTP bioassays, intestinal hyperplasia was
not observed in rats in either study at any doses. In contrast,
diffuse hyperplasia occurred at similar incidence in the three
highest doses; yet adenoma incidence was only signiﬁcantly
elevated in the two highest doses relative to controls. The
presence of hyperplasia with and without tumor formation
suggests that Cr(VI) induced cell proliferation independent of
mutagenesis. These data suggest that the proliferation observed
in mice is a necessary precursor for the development of
intestinal neoplasms and plays a role in initiation and/or
promotion but is not necessarily indicative of tumorigenesis.
Key Event 5: DNA Modiﬁcation
The ﬁfth key event in the hypothesized MOA for the mouse
intestinal tumors involves DNA modiﬁcation. An important
part of MOA analysis is an evaluation of the mutagenicity and
genotoxicity of the compound of interest. Carcinogens can be
broadly classiﬁed as either DNA-reactive carcinogens or
epigenetic carcinogens (Baccarelli and Bollati, 2009; Boobis
et al., 2009; Williams, 2008). The ability of chromium to
directly induce DNA damage has been studied extensively and
is summarized below. However, evidence of direct interaction
with DNA in and of itself does not demonstrate that a speciﬁc
tumor arises as a result of a DNA-reactive MOA. In fact, there
is growing evidence that chromium may act via epigenetic
mechanisms.
Direct DNA modiﬁcation. The reactivity of chromium with
DNA has been the subject of numerous studies and several
recent reviews (O’Brien et al.,2 0 0 3 ; Salnikow and Zhitkovich,
2008; Zhitkovich, 2005). Known and/or expected forms of
DNA damage associated with Cr(VI) exposure include DNA
adducts, single- and double-strand DNA breaks, inter- and
intrastrand cross-links, oxidative DNA damage, and replication
blockage. It is important to note that Cr(VI) itself is unreactive
toward DNA, but following uptake and intracellular reduction,
reduced chromium valence states, particularly Cr(V) and
Cr(III), can interact with DNA (Nickens et al., 2010; O’Brien
et al.,2 0 0 3 ; Zhitkovich, 2005). As was shown in Figure 5A,
binary Cr(III)-ligand complexes occur intracellularly, and these
can subsequently form ternary complexes with themselves
(e.g., GSH-Cr(III)-GSH) or with DNA (e.g., GSH-Cr(III)-DNA).
The ternary DNA complexes may comprise the majority of
Cr-DNA adducts (Arakawa et al., 2000; O’Brien et al., 2003;
Zhitkovich, 2005). Shuttle vector assays indicate that GSH and
amino acid chromium adducts predominantly lead to base pair
substitutions, whereas ascorbate-Cr adducts lead to equal
amounts of mutations and large genetic changes (Zhitkovich,
2005). These complexes can also lead to DNA-protein cross-
links (DPX). DNA interstrand cross-links are thought to
comprise much of the remaining direct Cr-DNA lesions
(O’Brien et al., 2003; Zhitkovich, 2005). Several lines of
evidence suggest that most Cr-DNA interaction occurs on the
phosphate backbone (Arakawa et al., 2000; O’Brien et al.,
2003). Repair of Cr-DNA lesions has recently been shown to
increase genotoxicity, as cells deﬁcient in either base or
nucleotide excision repair were more resistant to Cr(VI)
mutagenesis in vitro (Brooks et al., 2008). ROS may also
contribute to chromium-mediated genotoxicity. However, its
overall importance remains uncertain (Nickens et al., 2010;
O’Brien et al., 2003; Zhitkovich, 2005).
An important consideration for DNA reactivity is mutagenic
efﬁciency, which refers to the probability of a DNA adduct to
induce a heritable mutation in a normal cell (Jarabek et al.,
2009). In this regard, DNA damage in differentiated cells is
less likely to lead to heritable mutations (Jarabek et al., 2009).
An important consideration is whether Cr(VI) reaches target
cells in the intestine that possess proliferative potential.
Physically, unreduced Cr(VI) might come into direct contact
with proliferative crypt cells, but it is not known whether these
cells express the necessary transporters to readily absorb
Cr(VI). Conceivably, immature crypt cells may be unable to
transport Cr(VI), whereas villous cells may readily absorb
Cr(VI) resulting in oxidative stress, cytotoxicity, and re-
generative hyperplasia. Indeed, there is some evidence that
certain transporters might be more abundantly expressed in
differentiated cells (Markovich, 2001; Silberg et al., 1995). As
noted by Jarabek et al., (2009), some forms of DNA damage
are more prone to induce cytotoxicity than mutagenesis. DNA
damage caused by accumulation of Cr(VI) in mature
differentiated cells along the villous could lead to cytotoxicity
as opposed to mutagenesis. Thus, it is conceivable that Cr(VI)
has relatively low mutagenic efﬁciency.
FIG. 6. A comparison of histiocytic inﬁltration (HI), diffuse hyperplasia,
and adenomas in the duodenum of female mice and rats. The milligrams per
kilogram per day dose is the average daily ingested dose of Cr(VI) over the
study duration as reported in Stout et al. (2009a). The incidence data are as
reported in Table 1 herein. Note that hyperplasia and tumors were not observed
in rats.
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nonlinearities and thresholds that limit carcinogenicity (Hoel
and Portier, 1994; Williams, 2008). Table 3 lists several factors
that limit the carcinogenicity of DNA-reactive compounds and
summarizes what is currently known or hypothesized about
their potential role in the MOA for the intestinal tumors
observed in mice. Several of these factor relate to pharmaco-
kinetics including delivery to target tissues and target cells,
uptake into target cells, and intracellular (de)toxiﬁcation.
Additionally, many inherent aspects about DNA structure
(e.g., so-called junk DNA), DNA repair, and transformation
also limit the possibility of carcinogenicity of DNA-reactive
compounds—particularly in cells with a short life span.
However, as discussed in the next section, Cr(VI) might
induce epigenetic effects that in turn impact the inherent
barriers to carcinogenicity.
Epigenetic DNA modiﬁcations. Three recent reviews on the
genotoxicity and carcinogenicity of Cr(VI) have suggested that
chromium induces epigenetic changes (Holmes et al., 2008;
Nickens et al., 2010; Salnikow and Zhitkovich, 2008). Most of
the evidence for this form of DNA modiﬁcation derives from
studies that indicate that chromium increases genomic in-
stability, which is characterized by chromosomal instability
and/or microsatellite instability (MSI). The latter can be
observed in tumor cells where there is either shortening or
lengthening of repetitive DNA sequences that are prone to
replication error (Geigl et al., 2008; Grady and Carethers,
2008). MSI is often a result of the loss or hindrance of DNA
mismatch repair (MMR) genes such as MutL homolog 1
(MLH1). Indeed, some tumors exhibit hypermethylation of
MLH1, and thus, epigenetic silencing of MLH1 can result in an
MSI phenotype without mutation in MMR genes (Geigl et al.,
2008; Grady and Carethers, 2008).
Lung biopsies taken from workers occupationally exposed to
chromate exhibit fewer p53 point mutations than normally
expected in lung tumors (20 vs. ~50%). However 79% (30/38)
of these tumors had signs of MSI as compared with 15% (4/26)
in tumors from unexposed individuals (Hirose et al., 2002;
Kondo et al., 1997). Relative to lung tumors from nonexposed
individuals, tumors from chromate workers exhibit reduced
expression of MLH1 as well as signs of MLH1 hyper-
methylation (Takahashi et al., 2005). In vitro exposure of
cultured cells to Cr(VI) was shown to increase cellular
methylation of histone H3 lysine 9 (H3K9), which was
inhibited by pretreatment of cells with the antioxidant ascorbate
(Sun et al., 2009). Immunoprecipitation of methylated H3K9
following Cr(VI) exposure was shown to coprecipitate the
MLH1 promoter; moreover, the treatment of cells with Cr(VI)
produced time- and dose-dependent decreases in messenger
TABLE 3
Factors that Limit the Carcinogenicity of DNA-Reactive Carcinogens and Potential Relevance for the MOA of Mouse Small Intestine
Tumors Induced by Cr(VI)
Factors that limit carcinogenicity (Williams, 2008) Limits Cr(VI) carcinogenicity? Basis
Incomplete absorption/rapid excretion Yes Cr(VI) is reduced to Cr(III) in GI tract; Cr(III) is poorly
absorbed and excreted in the feces
Binding to extracellular molecules Yes Cr(VI) reduction to Cr(III) is mediated by binding to
organic molecules
Dilution upon systemic absorption Not applicable Point of contact effect, systemic absorption is not
applicable
Low probability of reaching target stem cells Yes Cr(VI) may be partially or entirely reduced to Cr(III)
before reaching the small intestine
Unknown Cr(VI) might not directly contact or be absorbed by
proliferative crypt cells of the small intestine
Limited cellular uptake/efﬁcient elimination at target site Yes Extracellular reduction of Cr(VI) to Cr(III) limits cellular
uptake
Unknown Crypt cells might not express necessary transporters for
absorption
Limited bioactivation or/efﬁcient detoxiﬁcation in target
cells
Unknown Intracellular reduction of Cr(VI) to Cr(III) might
generate free radicals as well as Cr(III)-L species
capable of interacting with DNA
Reaction with non-DNA nucleophiles Unknown (See previous)
Reaction with nonutilized regions of DNA Yes General phenomenon
Efﬁcient DNA repair Unknown Cr(VI) might induce epigenetic changes that inhibit
DNA repair
Low probability of producing transforming mutations in
multiple critical genes
Unknown Potential epigenetic factors
Infrequency of neoplastic development from
preneoplastic lesion
Unknown Persistent diffuse hyperplasia might increase the chance
of neoplastic development
MOA FRAMEWORK FOR THE ORAL CARCINOGENICITY OF CR(VI) 29RNA (mRNA) levels of MLH1 (Sun et al.,2 0 0 9 ). It has also
been shown that chromium can cross-link histone remodeling
enzymes, thereby inﬂuencing gene expression (Schnekenburger
et al.,2 0 0 7 ).
Salnikow and Zhitkovich (2008) have also posited that
Cr(VI)-induced carcinogenesis might involve genomic in-
stability arising through effects on MMR genes (Salnikow
and Zhitkovich, 2008). These authors reported that several cell
lines deﬁcient in MMR genes were resistant to Cr(VI)-induced
toxicity (Peterson-Roth et al., 2005). Zhitkovich and col-
leagues argue that exposure to Cr(VI) might selectively inhibit
the growth or promote the death of normal cells but that cells
deﬁcient in MMR ‘‘due to spontaneous mutagenesis and
epigenetic changes’’ would continue to proliferate and acquire
more mutations because of their insensitivity to Cr(VI)
(Peterson-Roth et al., 2005). This ‘‘selective outgrowth’’ would
result in an MSI phenotype as observed in the tumors from
chromate workers (Hirose et al., 2002; Kondo et al., 1997;
Takahashi et al., 2005). However, one recent study reported
that human bronchial epithelial cells immortalized by repeated
passage in low concentrations of Cr(VI) did not show
involvement of MLH1 or MSI (Rodrigues et al., 2009).
In vivo evidence of DNA modiﬁcation. Although the
evidence for chromium-induced DNA damage in vitro is
convincing, the evidence for Cr(VI)-induced genotoxicity
in vivo is comparatively weak, particularly when administered
via drinking water (Nickens et al., 2010). Recent reviews on
the carcinogenicity of Cr(VI) cite several subchronic studies as
providing evidence for in vivo genotoxicity (McCarroll et al.,
2010; Sedman et al., 2006; Supplementary table 1). As noted in
Supplementary table 1, many of these subchronic studies cited
in these two reviews employed relatively high doses of
Cr(VI)—some higher than those used in the 2-year NTP
cancer bioassay (NTP, 2008b). Of the studies noted by
McCarroll et al. (2010) and Sedman et al. (2006), ﬁve
involved oral exposure of rats to Cr(VI) and reported positive
responses for genotoxicity in tissues such as bone marrow,
liver, brain, or blood cells (Bagchi et al., 1995a,b, 1997;
Bigaliev et al.,1 9 7 7 ; Coogan et al., 1991); yet, no tumors
occurred in any of these tissues in rats in the 2-year NTP study.
Three of these studies attributed the genotoxicity to oxidative
mechanisms, not direct DNA reactivity (Bagchi et al., 1995a,b,
1997).
Four studies in mice (excluding micronucleus studies) were
previously cited as demonstrating genotoxicity (McCarroll
et al., 2010; Sedman et al., 2006). Two of the four studies
reported gene mutation following ip administration (Itoh and
Shimada, 1996; Knudsen, 1980), a route of exposure that has
very little relevance when evaluating effects of Cr(VI)
following oral exposure, as ip administration bypasses the
protective reductive mechanisms described earlier for Key
Event 1. A third study, Bagchi et al. (2002), reported DNA
damage in liver and brain tissue within 24–96 h after oral
gavage of relatively high doses of   6 mg/kg Cr(VI), which the
authors attributed to oxidative mechanisms. The fourth study,
Dana Devi et al. (2001), reported increased DNA damage in
leukocytes via the comet assay within 24 h of exposure. In the
NTP study, chronic exposure to doses that are comparable to
those Dana Devi et al. (2001) reported to induce DNA damage
in leukocytes did not result in tumors among mice in any tissue
other than the small intestines; moreover, in the NTP study,
there was no apparent toxicity to leukocytes (NTP, 2008b).
Further, the gavage doses used by Dana Devi et al. (2001)
(~0.18 to 24 mg/kg Cr(VI)), with the possible exception of the
lowest dose, were likely sufﬁcient to exceed the reductive
capacity of the GI tract and thus may have resulted in increased
absorption and oxidative stress as reported by Bagchi et al.
(1995a,b, 1997, 2002). Importantly, the comet assay measures
DNA damage (not mutation), and oxidative DNA damage has
been shown increase tail lengths in leukocytes (Collins et al.,
2008); thus, the ﬁndings by Dana Devi et al. (2001) may relate
to oxidative stress as opposed to direct Cr(VI) DNA damage. In
this regard, in vitro exposures of human lymphocytes to Cr(III)
and Cr(VI) suggest that comet tails induced by the latter are
likely the result of oxidative mechanisms as evidenced by the
shortening of tail moments by incubation with catalase and
their lengthening by posttreatment with endonuclease III,
which nicks DNA at oxidized bases (Blasiak and Kowalik,
2000).
Several studies have examined micronucleus formation in
bone marrow (Supplementary table 1). All studies involving ip
administration were positive and employed doses of   10 mg/kg
potassium chromate (~3 mg/kg of Cr(VI)). As noted above,
this route of exposure has very limited application for under-
standing the MOA from drinking water exposure to Cr(VI).
Among several oral exposure studies, only one has reported
positive ﬁndings of chromosomal aberrations in bone marrow of
Swiss mice (Sarkar et al.,1 9 9 3 ). It is noteworthy that many of
the studies reporting positive ﬁndings for genetic damage from
ip exposure to Cr(VI) have employed doses (on a milligrams per
kilogram basis) greater than the lowest dose in the NTP study
and in some cases doses that exceed the highest doses tested by
NTP (Supplementary table 1).
Several studies that have directly compared the micronu-
cleus formation of Cr(VI) by administration in drinking water
(or oral gavage) and ip injection suggest that only ip
administration results in genotoxicity. Shindo et al. (1989)
exposed two strains of mice (CD-1 and MS/Ae) to several
concentrations of Cr(VI) via oral gavage and by ip injection.
In both strains of mice, there was a dose-dependent decrease
in polychromatic erythrocytes (PCEs) and an increase in
micronucleated PCEs following ip administration but not
following gavage (Shindo et al., 1989). Similarly, De Flora
et al. (2006) showed that ip administration of 17.7 mg/kg
Cr(VI) to 8-month-old male BDF1 mice resulted in a
signiﬁcant increase in micronucleated PCEs, whereas gavage
of the same dose did not. De Flora et al. (2006) showed that
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drinking water for 20 days showed no increase in micro-
nucleated normochromatic erythrocytes (NCEs) at 5, 12, and
20 days of exposure or micronucleated PCEs at day 20.
They also exposed 2-month-old mice to 5, 50, and 500 mg
Cr(VI)/l in drinking water for up to 210 days. No changes in
micronucleated NCEs were observed after 14, 28, 56, and 146
days of exposure. A slight but statistically insigniﬁcant
increase was observed in micronucleated PCEs in the highest
dose group relative to controls (i.e., 2.38 vs. 1.83% PCE). De
Flora et al. (2006) also showed that pregnant Swiss albino
mice exposed to 5 and 10 mg of Cr(VI)/l in drinking water
throughout pregnancy showed no signiﬁcant increase in
micronucleated PCEs in the bone marrow. Similarly, no
increases in micronucleated PCEs were found in the livers or
peripheral blood of the fetuses. In contrast, rats administered
an ip dose of 50 mg/kg on day 17 of pregnancy demonstrated
signiﬁcant increases in bone marrow micronucleated PCEs
and in the liver and peripheral blood of the fetuses (De Flora
et al., 2006). These studies, employing direct comparisons of
oral and ip exposure routes, strongly suggest that gastric
reduction of Cr(VI) can protect against genotoxicity in blood
cells and other tissues.
Mirsalis et al. (1996) reported that 1–20 mg Cr(VI)/l did not
induce micronucleus formation in mice exposed by drinking
water (ad libitum 48 h) or gavage (two treatments for 2
consecutive days). Similar ﬁndings were observed in the NTP
90-day drinking water study (NTP, 2007). Male and female
B6C3F1 mice exposed to ~20 to 350 mg/l Cr(VI) showed no
signiﬁcant increase in micronucleated NCE. NTP (2007) also
carried out a comparative study where three strains of male
mice were exposed for 90 days to roughly 20, 45, and 90 mg/l
Cr(VI). In this study, unlike in the 2-year study, B6C3F1 mice
showed an increase in micronuclei formation, but it was judged
to be equivocal because no dose group showed a signiﬁcant
increase over the control. In BALB/c mice, no increase was
observed, whereas in a transgenic C57BL/6 mouse strain, there
was a signiﬁcant increase of micronucleated NCEs at the
highest dose group (90 mg/l).
To date, the only study that has addressed Cr(VI)-induced
genotoxicity in the target tissue of interest (i.e., small intestine)
measured DPX and oxidative DNA damage (De Flora et al.,
2008). In this study, De Flora et al. (2008) exposed female
SKH-1 hairless mice to 5 and 20 mg Cr(VI)/l in drinking water
for 9 months and examined genotoxic damage in blood cells
and the GI tract. They found no signiﬁcant changes in either
DPX or 8-hydroxy-2#-deoxyguanosine (8-OH-dG) formation
in the forestomach, glandular stomach, or duodenum after
9 months of exposure. The investigators also treated mucosal
scrapings from the forestomach, glandular stomach, and
duodenum of untreated animals with Cr(VI) in vitro and found
signiﬁcant increases in DPX and 8-OH-dG formation.
Together, these ﬁndings underscore that Cr(VI) can be
genotoxic in vitro without inducing genotoxicity in vivo when
ingested orally in drinking water because Cr(VI), below certain
concentrations, can be reduced to Cr(III) before entering cells.
It should be noted that the lack of oxidative DNA damage at  
20 mg/l Cr(VI) does not preclude changes in redox status in the
tissue, as changes in redox can occur without inducing DNA
damage.
Two studies have reported that coexposure to intense
artiﬁcial ultraviolet radiation and Cr(VI) (as potassium
chromate)in drinking water at 0.5, 2.5, and 5 mg/l resulted in
an increased occurrence of skin tumors in hairless mice
(Davidson et al., 2004; Uddin et al., 2007). At 5 mg/l, an
increase in the chromium content of the skin was also reported.
Although some have posited that this indicates that Cr(VI) was
systemically absorbed and distributed to the skin, others have
speculated that dermal exposure to Cr(VI) during the experi-
ments might have occurred (Salnikow and Zhitkovich, 2008).
Regardless, these ﬁndings are of questionable relevance to
humans because Cr(VI)-exposed workers have not been shown
to have an increase in skin cancer despite substantial systemic
and dermal exposures (ATSDR, 2008; IARC, 1990; U.S. EPA,
1998).
Key Event 6: Mutagenesis
Although the speciﬁc genetic alterations that resulted in
tumor formation in the small intestine of mice in the NTP study
are not known, several lines of evidence suggest that the
genetic damage might be the result of epigenetic changes that
lead to genomic instability. Experimentally, exposure of
transgenic gpt
þ Chinese hamster V79 ﬁbroblasts to soluble
potassium chromate has been shown to induce mutant colonies
with apparent transgene (gpt) deletions, many of which turned
out to be silenced through hypermethylation in the promoter
region; moreover, many mutants could be reverted by
inhibition of DNA methylation (Klein et al., 2002). In contrast,
transgene deletions induced by exposure to insoluble chromate
were not hypermethylated (Klein et al., 2002). These data
suggest that Cr(VI) can exert epigenetic gene silencing by
aberrant DNA methylation. MSI is a common trait in 15–20%
of human colorectal cancers (Geigl et al., 2008; Grady and
Carethers, 2008). MSI is often a result of the loss or hindrance
of DNA MMR, and nearly a third of individuals with colorectal
cancers characterized by MSI have hereditary mutations in
genes involved with MMR such as MLH1; moreover, 15–20%
of the sporadic cases with MSI exhibit hypermethylation of
MLH1 (Geigl et al., 2008; Grady and Carethers, 2008). MSI,
including MLH1 hypermethylation, has also been found in
a number of human tumors of the small intestine (Ruemmele
et al., 2009). As previously described, lung biopsies taken from
workers occupationally exposed to chromate exhibit an MSI
phenotype and signs of MLH1 hypermethylation (Hirose et al.,
2002; Kondo et al., 1997; Takahashi et al., 2005).
An important uncertainty in Cr(VI)-induced intestinal
carcinogenesis is whether DNA modiﬁcation occurs early or
late in the process. According to Grady and Carethers (2008),
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However, in the context of environmental exposure to Cr(VI),
this should not be confused with occurring early in the MOA.
In the MOA proposed herein, pharmacokinetic and pharmaco-
dynamic processes precede DNA modiﬁcation and tumorigen-
esis. In the context of risk assessment, mutagenesis has been
argued to be an early key event ‘‘that initiates a cascade of
other key events such as cytotoxicity or cell proliferation’’ for
chemicals that have a ‘‘mutagenic MOA’’ (U.S. EPA, 2007).
Because studies on Cr(III) administered as chromium picoli-
nate show increased cellular chromium levels but no car-
cinogenic effects (NTP, 2008a), intracellular chromium cannot
unequivocally be considered to be a mutagen that acts through
a ‘‘linear’’ MOA. Considering further that intestinal tumors
induced by Cr(VI) in mice appear to associate with prolonged
diffuse hyperplasia, it seems more likely that prolonged
proliferative pressure may increase the chance of a spontaneous
mutation and/or otherwise promote clonal expansion of
initiated cells (including those with genomic instability). It is
worth noting that analysis of DNA from the tumors observed in
the NTP 2-year bioassay (NTP, 2008b) has the potential to
provide important information regarding the MOA. As Kondo
et al. (1997) remarked regarding lung tumors in chromate
workers, ‘‘it is necessary to test samples from chromate lung
cancer patients for mutations in other cancer-associated genes,
gene instability, loss of heterozygosity, and chromosomal
aberrations in an effort to elucidate the mechanisms involved in
carcinogenesis in chromate workers.’’ However, to the best of
our knowledge, such an analysis has not been undertaken for
tumors observed in the NTP rodent study.
Plausibility
The MOA Framework (U.S. EPA, 2005) includes evaluation
of the proposed MOA using causality criteria originally
proposed by Sir Bradford Hill (Hill, 1965). Plausibility of the
proposed MOA, consideration of alternative MOAs, and
comparison with MOAs for chemicals that cause similar
tumors are important factors that touch upon the Hill criteria. In
regard to plausibility, the MOA presented herein is consistent
with general principles of carcinogenesis and the ﬁndings of
the 2-year NTP study, which suggest that (1) there is no
evidence of cancer from Cr(VI) exposure in drinking water
outside the alimentary canal, (2) neoplasms in the small
intestine occurred at doses that likely greatly exceeded the
reductive capacity of the proximal portions of alimentary canal,
and (3) proliferation occurred relatively early after exposure
and at lower doses than tumorigenesis. Considering that no
neoplasms were found in tissues other than those lining the
alimentary canal, systemic absorption of Cr(VI) seems unlikely
to pose a carcinogenic risk. Similarly, there is little evidence of
cancers outside the respiratory tract following inhalation
exposures in animals or humans (De Flora, 2000), and
occupational exposures to Cr(VI) have not been shown to
cause GI tract cancers despite evidence of substantial incidental
ingestion (Gatto et al., 2010). Figure 7 outlines the causal and
temporal relationships as well as data gaps for proposed key
events in the MOA.
Figure 6 depicts the dose-response concordance of the key
events in the hypothesized MOA. On a milligrams per
kilogram basis, mice and rats ingested roughly equivalent
doses of Cr(VI) in the 2-year NTP bioassays. Whereas there is
a dose-dependent increase in histiocytic inﬁltration in both
species, dose-dependent increases in hyperplasia and adenomas
in the small intestine were only observed in mice. The ﬁgure
indicates that diffuse hyperplasia occurs at similar incidence
levels in tumorigenic and some nontumorigenic doses, in-
dicating that the observed proliferation may be antecedent to
carcinogenesis. The ﬁndings also suggest that proliferation
itself may not be sufﬁcient to cause carcinogenesis but that
coupled with additional and prolonged duodenal exposure to
unreduced Cr(VI) increases the risk of carcinogenesis. From
a temporal standpoint, the early onset of hyperplasia (by 90
days) and long time to tumor is more consistent with Cr(VI)
carcinogenesis arising secondary to the onset of tissue damage
and cell proliferation than direct Cr(VI)-induced mutagenesis.
Alternative MOA Constructs for Framing Available Data
Alternative MOAs include mutation as an early key event as
described by McCarroll et al. (2010). Based on currently
available data, these investigators concluded that the weight of
evidence supports a mutagenic MOA based on the genetic
activity proﬁle for Cr(VI) and evidence that DNA damage was
observed in circulating lymphocytes within 24 h following oral
gavage of Cr(VI) at doses similar to that administered in the
NTP study (Dana Devi et al., 2001). Although there are some
similarities in the MOA proposed by McCarroll et al. (2010)
and that proposed herein, differences include the sequence of
key events (e.g., occurrence of mutagenesis as an initiating or
FIG. 7. Causal and temporal associations supporting Key Events in the
hypothesized MOA for intestinal tumors. Each bar represents where Key
Events have been observed, inferred, or hypothesized. It is noted that DNA
modiﬁcation and mutagenesis could occur below the doses where tumors were
observed. The arrow indicates concentration (62.5 mg/l SDD) where cell
proliferation was observed in the 90-day NTP (2007) study.
32 THOMPSON ET AL.later key event), the inclusion of critical pharmacokinetic steps
(saturation of GI reductive capacity and absorption into
intestinal epithelium), and consideration of epigenetic changes
consistent with intestinal cancers (e.g., MMR genes).
Similarities with Other Duodenal Carcinogens in 2-Year
Bioassays
In their summary of the ﬁndings of the 2-year bioassay of
Cr(VI) in drinking water, Stout et al. (2009a) noted that captan
was the only other compound examined by NTP that resulted
in both benign and malignant intestinal neoplasms of epithelial
origin attributed to chemical exposure (NCI, 1977). As such,
the MOA for captan (and the structurally similar folpet) may
provide important insights for understanding the intestinal
tumors observed in mice exposed to Cr(VI) in drinking water.
Like Cr(VI), captan and folpet are clearly mutagenic in vitro,
but evidence for in vivo mutagenicity is equivocal or negative
(Arce et al., 2010; Bernard and Gordon, 2000). Captan and
folpet react readily with thiols (e.g., GSH, cysteine, and pro-
teins) and induce blunted villi and villous cytotoxicity, rege-
nerative crypt cell proliferation, and neoplasms (adenomas and
carcinomas) in the mouse duodenum and, to a lesser extent,
jejunum (Cohen et al., 2010). In 2004, the U.S. EPA changed
their cancer classiﬁcation of captan from ‘‘a probable human
carcinogen’’ (Category B) to ‘‘not likely’’ after an independent
peer review concluded that captan acted through a nonmutagen
threshold MOA that ‘‘required prolonged irritation of the
duodenal villi as the initial key event’’ (Gordon, 2007; U.S.
EPA, 2004). The similarities between captan, folpet, and
Cr(VI) make it plausible that they share a common MOA, i.e.,
cytotoxicity in villous cells, thereby placing sustained pro-
liferative pressure on crypt cells that increase the risk of
carcinogenesis. Notably, an explanation for the absence of
intestinal tumors in rats following exposure to captan and
folpet is not known; yet, Cohen et al. (2010) concluded that the
MOA in mice might be relevant to humans under chronic high-
dose exposures.
Relevance to Humans
The data set available to assess relevance to humans is
relatively robust for Cr(VI)-induced carcinogenicity with the
most reliable ﬁndings derived from occupational epidemiology
studies of Cr(VI)-exposed workers. Although occupational
exposure occurs primarily by inhalation, historical worker
exposures in some industries were extremely high and caused
GI disorders including ulcers, diarrhea, and abdominal pain
(NIOSH 1975; PHS 1956). It is probable that at the extreme
exposures experienced by workers in some historical in-
dustries, oral exposures from incidental ingestion of inspired
particulates and hand to mouth contact were signiﬁcant as
evidenced by yellow staining of teeth and tongues among
workers of the historical chromate production industry (PHS,
1956).
Well over 100 epidemiological studies in Cr(VI)-exposed
workers have been published. Although these studies mostly
focus on lung cancer, dozens have also examined associations
between chromium exposure and cancers outside the res-
piratory system. A systematic review of literature reporting on
GI tract cancers among workers with known occupational
exposure to Cr(VI) and meta-analysis of 32 studies published
since 1950 did not ﬁnd an association (Gatto et al., 2010).
Meta-standardized mortality ratios (meta-SMRs) calculated for
cancers of the oral cavity, esophagus, stomach, colon, and
rectum of Cr(VI)-exposed workers were generally around 1.0,
and none were signiﬁcantly elevated—even among more
highly exposed subcohorts (Fig. 8). Gatto et al. (2010)
identiﬁed only three studies reporting small intestine cancer
among Cr(VI)-exposed workers, all with insufﬁcient sample
size to develop a meta-SMR. All three studies reporting on
small intestine cancers were based on a very small number of
cases (n < 3) with no signiﬁcant increases reported (Gatto
et al., 2010), an observation that is not consistent for an
association between Cr(VI) exposure and small intestine
tumors in humans.
Several epidemiologic studies have investigated cancer
incidence or mortality among populations with environmen-
tal exposures to chromium or Cr(VI) by drinking water or
contaminated soil and found no increases in cancer risk
(Armienta-Hernandez and Rodriguez-Castillo, 1995; Bednar
and Kies, 1991; Fryzek et al., 2001; GGHB, 1991; GTBH,
1989). However, these studies are ecologic and limited by the
quality and availability of reliable information on exposure
and/or outcome. Studies of Chinese villagers possibly
exposed to very high concentrations of Cr(VI) in drinking
water have reported an increase in stomach cancer mor-
tality (Beaumont et al., 2008; Zhang and Li, 1987). However,
other investigations of the same population found no dose-
response for Cr(VI) exposure and stomach cancer mortality
using three different exposure metrics (Kerger et al., 2009).
Kerger et al. (2009) concluded that the increased risk was
because of differences in demographic factors for rural and
urban communities. It is important to consider that the
original mortality and exposure data, upon which all these
epidemiologic studies are based, are of questionable use-
fulness because the mortality data are crude and cannot be
corrected for age or gender. Furthermore, the person-years at
risk can only be roughly estimated, and there are signiﬁcant
concerns regarding the classiﬁcation of exposure status.
Follow-up for cancer mortality in this study is only 4–14
years following initial exposure, and latency for stomach
cancer is expected to be greater than 20 years. For example,
latency for stomach cancer associated with asbestos exposure
is 20–40 years (Levine, 1985), with Helicobacter pylori
infection is 50 years (Correa, 2004) ,a n dw i t hi o n i z i n g
radiation is 20–30 years (Mossman, 1984). Therefore, temporal
MOA FRAMEWORK FOR THE ORAL CARCINOGENICITY OF CR(VI) 33ambiguity is a very signiﬁcant concern in the studies of the
exposed Chinese population. Given these, and likely other
serious limitations, ﬁndings from the Chinese villagers studies
should not be considered reliable evidence regarding the human
relevance of GI tract cancers from drinking water exposure to
Cr(VI).
Although there is an abundance of quality studies in-
vestigating GI tract cancers in humans exposed to Cr(VI) in
occupational settings, differences in toxicokinetics between
drinking water and occupational exposure, as well as in the
pattern, duration, and frequency of exposure, present un-
certainty as to whether data from occupational studies are
useful to assess risk from long-term drinking water exposure.
Also, studies of populations exposed environmentally to
Cr(VI) are generally null regarding GI tract cancers. Given
the breadth of epidemiologic data, ﬁndings from these studies
indicate that human relevance is not likely or only relevant at
very high levels of exposure.
The key events in the proposed MOA for intestinal tumors in
mice are thought to be potentially relevant to humans, meaning
that from prolonged and relatively high Cr(VI) exposures
the proposed key events are qualitatively relevant. However,
quantitative relevance is questionable because, like rodents,
systemic bioavailability of Cr(VI) is limited by reduction of
Cr(VI) to Cr(III) in the human stomach (De Flora, 2000; Febel
et al., 2001; Finley et al., 1997). Finley et al. (1997) reported
no increase in urinary or blood chromium of humans
consuming Cr(VI) in water at the current federal drinking
water standard of 0.1 mg/l Cr(VI), suggesting that drinking
water exposure at this level is entirely reduced to Cr(III) before
systemic absorption. At higher concentrations (approximately
  5 mg/l Cr(VI)), Finley et al. (1997) reported that chromium
concentrations in blood and urine were increased. These data
suggest that in humans, similar to rodents, there is a saturation
level for stomach reductive capacity. Another explanation is
that at the higher concentrations, greater amounts of Cr(III)
were absorbed (Finley et al., 1997). A better understanding of
Cr(VI) disposition in rodents through the development of
pharmacokinetic models could inform the disposition of Cr(VI)
in humans as well assess whether the MOA for mouse tumors
is relevant to humans.
It is noteworthy, though perhaps coincidental, that the
hypothesized MOA for Cr(VI)-induced intestinal tumors in
mice shares certain aspects with human intestinal carcinogen-
esis. Inﬂammation and irritation are thought to play key roles in
human diseases of the intestines such as Crohn’s disease
(Coussens and Werb, 2002; Ryan, 1996; Thun et al., 2004).
Thus, if Cr(VI) concentrations were sufﬁciently high to exceed
reductive capacity of the upper alimentary canal for an ex-
tended time, possible key events in the mouse MOA (irritation,
inﬂammation, hyperplasia, and genetic damage) might be
qualitatively relevant to humans. Similarly, MSI and MMR
FIG. 8. Standardized mortality ratio (SMR) risk estimates from epidemiologic studies that evaluated occupational exposure to Cr(VI) and risk of oral (A),
stomach (B), and colon cancers (C).
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small intestines, and chromium may very well affect these
genes and/or induce genomic instability (Geigl et al., 2008;
Grady and Carethers, 2008; Heyer et al., 1999; Holmes et al.,
2008; Nickens et al., 2010; Sun et al., 2009). These and other
heritable genetic variations are associated with intestinal
cancer and may be predictive of cancer risk (Geigl et al.,
2008; Tokuoka et al., 2009; Walther et al., 2009). The in-
ﬂuence of chromium on these genes within the intestines is not
known.
DATA GAPS IN THE MOA
This critical review of the scientiﬁc literature for purposes of
developing a plausible MOA underlying intestinal tumors
observed in mice exposed to Cr(VI) in drinking water resulted
in the identiﬁcation of several data gaps and uncertainties in the
MOA that could be addressed through targeted research (Table 4).
The differences in the intestinal response to Cr(VI) in rats and
mice suggest differences in pharmacokinetics—speciﬁcally
reduction of Cr(VI) to Cr(III) in the lumen of the upper GI
tract and the intestinal uptake of Cr(VI) through anion
transporters. Target tissue data for chromium are needed to
better understand if the differential responses are pharmacoki-
netic or pharmacodynamic in nature, or both. Gastric ﬂuids from
humans, mice, and rats are needed to measure reduction rate and
capacity—which can be important for parameterizing species-
speciﬁc PBPK models. Such models capable of reasonably
estimating dosimetry in rodents and predicting dosimetry in
humans could be very informative in the context of un-
derstanding potential human health risks. From an experimental
perspective, one could use such models to predict the species-
speciﬁc administered dose of Cr(VI) needed to induce key
events in the MOA and then test those predictions experimen-
tally.
There are currently no data to determine whether the
intestinal tissue in mice experienced oxidative stress. However,
it is assumed to occur because of the intracellular reduction of
Cr(VI) (as explained in Key Event 3: Oxidative Stress Leading
to Tissue Damage and Inﬂammation section). Direct measures
of oxidative stress, such as the ratio of reduced to oxidized
GSH and transcript changes related to oxidative stress path-
ways, could provide important information to better understand
the potential role of oxidative stress. The role of inﬂammatory
responses in the MOA could be assessed through measures of
cytokines in target tissues. Because histopathology was
performed by the NTP following exposures at 90 days and 2
years, the data available for cell proliferation as a key event are
more complete. However, a no effect level for hyperplasia in
the mouse duodenum was not identiﬁed; thus, one important
data gap is the identiﬁcation of a dose below which cell
proliferation does not occur in mice. Additionally, the species
differences in intestinal proliferation might involve unknown
toxicodynamic differences that could be informed by transcript
changes related to cell cycle.
Although De Flora et al. (2008) found no genotoxicity in
target tissues of the small intestine at drinking water exposures
of 5 and 20 mg/l Cr(VI), several important data gaps remain for
DNA modiﬁcation as a key event. Speciﬁcally, it is not known
whether direct chromium-mediated genotoxicity occurred in
the NTP study and whether genotoxicity is an early initiating
event or occurs much later in the sequence of events.
Examining genomic DNA samples from target tissue for the
presence of chromium adducts following administration of
Cr(VI) would be informative regarding the type of DNA
modiﬁcation or damage that occurred. Given the potential
involvement of oxidative stress, measures of oxidative DNA
damage at doses that caused tumors in mice would also be
informative. Again, changes in gene transcripts might inform
the types of DNA modiﬁcation and repair pathways induced by
Cr(VI) exposure.
Recent studies implicating epigenetic changes in DNA
following chromium exposure highlight the need to look for
such changes in the intestinal tissue—especially because
intestinal cancer is associated with some of the same changes
(e.g., MMR genes). If a similar evaluation of the mouse
intestinal tumors from the NTP (2008b) study was performed
as in the lung tumors from chromate workers (Kondo et al.,
1997), the role of epigenetic changes might be better informed.
Short of repeating a 2-year bioassay, changes in mRNA
transcripts related to MMR pathways, as well as changes in
DNA and histone methylation, might be observable in
a subchronic study and provide information regarding the
mechanisms of mutagenicity.
An important unresolved question is whether mutagenesis is
an early key event in the MOA or whether it occurs after
saturation of Cr(VI) reduction and the induction of cell
proliferation. Thus, it might be worthwhile to measure
in vivo mutation in various hot spots such as p53 or the ras
codons implicated in colon cancer or genes related to genomic
instability. Such an approach was recently performed in rats
following subchronic exposure to formaldehyde (Meng et al.,
2010).
Studies designed to address the above data gaps would not
only reﬁne the hypothesized MOA but could also lead to new
insights or even support other proposed MOAs. To further
elucidate the MOA underlying the intestinal tumors in mice
(Fig. 2), pharmacokinetic and pharmacodynamic data can be
compared between the responsive mouse intestine and the
unresponsive rat intestine. Similarly, pharmacokinetic and
pharmacodynamic data from the mouse duodenum and
jejunum could be compared with and correlated with the
diffuse hyperplasia and tumor formation that were elevated
further down the small intestine as Cr(VI) drinking water
concentration increased. Potentially, the pattern of key events
that occur in the jejunum (e.g., uptake, redox, transcript
changes, and proliferation) at higher concentrations would
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lower concentrations and further substantiate the MOA.
DISCUSSION
The U.S. EPA MOA Framework has been used to conduct
an analysis of the likely key events leading to the development
of intestinal tumors in mice chronically exposed to Cr(VI) in
drinking water. The available data suggest that the hypothe-
sized MOA in mice (Fig. 2) is plausible; however, additional
data are needed to support (or refute) this MOA and to help
explain the interspecies differences in response, as well as
better understand human relevance (Fig. 1). Studies aimed at
ﬁlling the data gaps in the MOA in rodents (Table 4) could
provide important information concerning human relevance
and low-dose extrapolation methods appropriate for risk assess-
ment. Studies designed to address the data gaps described
above are currently underway and should be completed by the
end of 2010.
With regard to low-dose extrapolation, it is well recognized
that mechanisms of toxicity and carcinogenicity of compounds
can change as a function of dose (Slikker et al., 2004).
Considering that the lowest tumorigenic Cr(VI) drinking water
concentration in the NTP (2008b) study (20 mg/l) is 1000 times
greater than the 95th percentile of U.S. Cr(VI) drinking water
concentrations (Supplementary fig. 1), it is critical to un-
derstand the MOA at the tumorigenic doses in order to
understand the risk at environmental exposure levels. Even if
direct DNA reactivity is a component in the intestinal tumor
formation in mice, the absence of such tumors in rats suggests
that there are one or more barriers to the induction of intestinal
tumor formation in some species and that it is worthwhile to
identify those barriers.
U.S. EPA (2005) indicates that even chemicals with direct
DNA reactivity might act through a nonlinear MOA and thus
support nonlinear low-dose extrapolation if such can be
reasonably demonstrated and/or expected:
A nonlinear approach should be selected when there are
sufﬁcient data to ascertain the mode of action and conclude that
it is not linear at low doses and the agent does not demonstrate
mutagenic or other activity consistent with linearity at low
doses. Special attention is important when the data support
a nonlinear mode of action but there is also a suggestion of
TABLE 4
Data Gaps in the MOA for Cr(VI)-induced Intestinal Cancers and Studies Needed to Address These Gaps
Key event Data gap Studies needed
(i) Sustained saturation of the reductive capacity
of the upper alimentary
Are there species differences in the reductive
capacity of the upper alimentary canal? Are
there dose-dependent transitions in the kinetics
of Cr(VI)? Is there a dose at which Cr(VI) will
be completely reduced in the stomach?
Pharmacokinetic data on the disposition of
chromium in rats and mice. Measures of the
reduction rate and capacity of gastric ﬂuid.
Development of a PBPK model capable of
predicting chromium disposition in multiple
species.
(ii) Uptake of Cr(VI) from the intestinal lumen Did unreduced Cr(VI) get passed into the lumen
of the duodenum at all doses? Did unreduced
Cr(VI) reach the jejunum? Are there species
differences in anion transporters that affect
Cr(VI) uptake? Is Cr(VI) taken up by
proliferating crypt cells?
Pharmacokinetic data including measures of
chromium in the glandular stomach, duodenum,
and jejunum, as well as the liver, kidney, femur,
blood (plasma and erythrocytes), urine, and
feces. Markers of Cr(VI) absorption in crypt
cells as compared with villi.
(iii) Oxidative stress, tissue damage, and
inﬂammation
Does unreduced Cr(VI) reaching the intestines
get taken into the epithelium and reduced
intracellularly? Does this lead to oxidative
stress and/or inﬂammation in the intestines?
Measures of oxidative stress, ratio of oxidized to
reduced GSH, inﬂammatory cytokines, and
changes in related genes in target tissues.
(iv) Cell proliferation Do lower doses than those used in the NTP study
induce intestinal diffuse hyperplasia? What is
the source of proliferation (cytotoxicity,
mitogenesis, etc.)?
Examination of histopathological and gene
expression changes indicative of cell
proliferation at lower drinking water
concentrations.
(v) DNA modiﬁcation Can chromium or oxidative DNA damage be
detected in DNA samples from target tissues
and cells? Are the tumors in the NTP study the
result of chromium-mediated DNA damage,
oxidative DNA damage, proliferative pressure,
or some combination? Does chromium induce
epigenetic changes?
Measures of chromium in genomic DNA
samples from target tissues. Measure 8-OH-
dG damage in target tissues. Assessment of
transcriptional changes related to DNA repair
genes in target tissues. Analysis of histone and
DNA methylation status in target tissues.
Expression level of MMR genes implicated in
chromium toxicity.
(vi) Mutagenesis Does Cr(VI) exposure induce measurable
increases in DNA mutations? Are there hot
spots for Cr(VI)-induced mutation?
In vivo mutation analysis of select codons (e.g.,
ras codons 12, 13, and 61) or exons (e.g., p53
exons 5–8) in frequently mutated targets.
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mutagenicity, the assessment may justify a conclusion that
mutagenicity is not operative at low doses and focus on
a nonlinear approach, or alternatively, the assessment may use
both linear and nonlinear approaches. (emphasis added)
Notably, a review of the dose-response shapes of 315
carcinogens previously studied by NTP and the National
Cancer Institute suggested that the dose-response for these
carcinogens is often nonlinear—even for carcinogens that test
positive in bacterial mutation assays (Hoel and Portier, 1994).
These authors concluded that the dose-response for other
endpoints (e.g., toxicokinetics, cell proliferation, and gene
expression) should be evaluated for informing the low-dose
risk estimation. Indeed, some of the proposed research
described above could inform the most appropriate low-dose
extrapolation approach for the oral carcinogenicity of Cr(VI).
To our knowledge, this is the ﬁrst practical example of using
MOA analysis to formally guide research for the purpose of
risk assessment. As demonstrated here using Cr(VI) as a case
study, MOA analysis has been shown to be a powerful tool to
guide future research by focusing on those studies that will be
most informative concerning potential human health risks. It is
not surprising that the data gaps identiﬁed in the hypothesized
MOA underlying the oral carcinogenicity of Cr(VI) would
require computational toxicology methods consistent with
those outlined in the National Academy of Sciences report
titled Toxicity Testing in the 21st Century: A Vision and
a Strategy (NAS, 2007). Such studies combine traditional
techniques, such as histopathology and biochemical measures,
with high throughput and high content approaches like
toxicogenomics. We believe that gathering such data is
essential to extrapolating the ﬁndings observed in the NTP
cancer bioassay to humans and will provide for a more
scientiﬁcally defensible assessment of human health risks.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci.
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